Skip to main content
Erschienen in: Digestive Diseases and Sciences 10/2019

29.04.2019 | Original Article

Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment

verfasst von: Corrine I. Voils, Heather A. King, Carolyn T. Thorpe, Dan V. Blalock, Ian M. Kronish, Bryce B. Reeve, Colleen Boatright, Ziad F. Gellad

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Nonadherence to direct-acting agents (DAAs) for hepatitis C (HCV) decreases viral response. To measure nonadherence to DAAs, a reliable, valid, and easily implemented method is needed.

Aims

The goals of this study were to refine a previously validated (in patients with hypertension) self-report measure of extent of nonadherence and reasons for nonadherence in the context of DAAs and to obtain initial evidence of content validity and reliability.

Methods

Phase I involved two focus groups with patients with HCV (n = 12) and one focus group with prescribers of HCV medications (n = 6) to establish content validity of reasons for nonadherence. Subsequent cognitive interviews with patients (n = 11) were conducted to refine items. Phase II was a prospective cohort study involving weekly administration of the refined measure by telephone to patients (n = 75) who are prescribed DAAs to evaluate reliability and consistency with viral response.

Results

In the cohort study, internal consistency ranged from acceptable (α = .69) to very high (α = 1.00) across time points and was quite high on average (α = .91). Across the 75 participants, there were 895 measurement occasions; of those, nonadherence was reported on only 27 occasions (3%), all of which occurred in the first 12 weeks. These 27 occasions represented 19 (26%) different individuals. At 12 weeks, 1 (1%) of patients had a detectable HCV viral load; at 12–24 weeks posttreatment, 4 (5%) had a sustained viral response. Nonadherent patients reported an average of 1.41 reasons for nonadherence.

Conclusions

This multi-method study established content validity of reasons for nonadherence and reliability of extent of nonadherence. High rates of adherence and viral response were consistent with previous studies using other nonadherence measurement methods.
Literatur
1.
Zurück zum Zitat Petruzziello A, Marigliano S, Loquercio G, et al. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22:7824–7840.CrossRefPubMedPubMedCentral Petruzziello A, Marigliano S, Loquercio G, et al. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22:7824–7840.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Kabiri M, Jazwinski AB, Roberts MS, et al. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med. 2014;161:170–180.CrossRefPubMedPubMedCentral Kabiri M, Jazwinski AB, Roberts MS, et al. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med. 2014;161:170–180.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Razavi H, ElKhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164–2170.CrossRefPubMed Razavi H, ElKhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164–2170.CrossRefPubMed
4.
Zurück zum Zitat van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama. 2012;308:2584–2593.CrossRefPubMed van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama. 2012;308:2584–2593.CrossRefPubMed
5.
Zurück zum Zitat Naggie S, Muir AJ. Oral combination therapies for hepatitis c virus infection: successes, challenges, and unmet needs. Annu Rev Med. 2017;68:345–358.CrossRefPubMed Naggie S, Muir AJ. Oral combination therapies for hepatitis c virus infection: successes, challenges, and unmet needs. Annu Rev Med. 2017;68:345–358.CrossRefPubMed
6.
Zurück zum Zitat Lo Re V 3rd, Teal V, Localio AR, et al. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med. 2011;155:353–360.CrossRefPubMed Lo Re V 3rd, Teal V, Localio AR, et al. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med. 2011;155:353–360.CrossRefPubMed
7.
Zurück zum Zitat McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–1069.CrossRefPubMed McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–1069.CrossRefPubMed
8.
Zurück zum Zitat Voils CI, Hoyle RH, Thorpe CT, et al. Improving the measurement of self-reported medication nonadherence. J Cin Epidemiol. 2011;64:250–254.CrossRef Voils CI, Hoyle RH, Thorpe CT, et al. Improving the measurement of self-reported medication nonadherence. J Cin Epidemiol. 2011;64:250–254.CrossRef
9.
Zurück zum Zitat Voils CI, King HA, Neelon B, et al. Characterizing weekly self-reported antihypertensive medication nonadherence across repeated occasions. Patient Preference Adherence. 2014;8:643–650.CrossRefPubMedPubMedCentral Voils CI, King HA, Neelon B, et al. Characterizing weekly self-reported antihypertensive medication nonadherence across repeated occasions. Patient Preference Adherence. 2014;8:643–650.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Voils CI, Maciejewski ML, Hoyle RH, et al. Initial validation of a self-report measure of the extent of and reasons for medication nonadherence. Med Care. 2012;50:1013–1019.CrossRefPubMedPubMedCentral Voils CI, Maciejewski ML, Hoyle RH, et al. Initial validation of a self-report measure of the extent of and reasons for medication nonadherence. Med Care. 2012;50:1013–1019.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Blalock DV, Zullig LL, Bosworth HB, et al. Self-reported medication nonadherence predicts cholesterol levels over time. J Psychosom Res. 2019;118:49–55.CrossRefPubMed Blalock DV, Zullig LL, Bosworth HB, et al. Self-reported medication nonadherence predicts cholesterol levels over time. J Psychosom Res. 2019;118:49–55.CrossRefPubMed
12.
Zurück zum Zitat Weidenbacher HJ, Beadles CA, Maciejewski ML, et al. Extent and reasons for nonadherence to antihypertensive, cholesterol, and diabetes medications: the association with depressive symptom burden in a sample of American veterans. Patient Preference Adherence. 2015;9:327–336.CrossRefPubMedPubMedCentral Weidenbacher HJ, Beadles CA, Maciejewski ML, et al. Extent and reasons for nonadherence to antihypertensive, cholesterol, and diabetes medications: the association with depressive symptom burden in a sample of American veterans. Patient Preference Adherence. 2015;9:327–336.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Cornelius T, Voils CI, Birk JL, et al. Identifying targets for cardiovascular medication adherence interventions through latent class analysis. Health Psychol. 2018;37:1006–1014.CrossRefPubMedPubMedCentral Cornelius T, Voils CI, Birk JL, et al. Identifying targets for cardiovascular medication adherence interventions through latent class analysis. Health Psychol. 2018;37:1006–1014.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Bonner JE, Esserman DA, Golin CE, et al. Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. J Clin Gastroenterol. 2015;49:76–83.CrossRefPubMedPubMedCentral Bonner JE, Esserman DA, Golin CE, et al. Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. J Clin Gastroenterol. 2015;49:76–83.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Evon DM, Esserman DA, Bonner JE, et al. Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. J Viral Hepatitis. 2013;20:536–549.CrossRef Evon DM, Esserman DA, Bonner JE, et al. Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. J Viral Hepatitis. 2013;20:536–549.CrossRef
16.
Zurück zum Zitat Evon DM, Golin CE, Bonner JE, et al. Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers. J Clin Gastroenterol. 2015;49:e41–e50.CrossRefPubMedPubMedCentral Evon DM, Golin CE, Bonner JE, et al. Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers. J Clin Gastroenterol. 2015;49:e41–e50.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Guest G, Namey E, McKenna K. How many focus groups are enough? Building an evidence base for nonprobability sample sizes. Field Methods. 2017;29:3–22.CrossRef Guest G, Namey E, McKenna K. How many focus groups are enough? Building an evidence base for nonprobability sample sizes. Field Methods. 2017;29:3–22.CrossRef
18.
Zurück zum Zitat Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15:1277–1288.CrossRefPubMed Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15:1277–1288.CrossRefPubMed
19.
Zurück zum Zitat Namey E, Guest G, McKenna K, et al. Evaluating bang for the buck: a cost-effectiveness comparison between individual interviews and focus groups based on thematic saturation levels. Am J Eval. 2016;37:425–440.CrossRef Namey E, Guest G, McKenna K, et al. Evaluating bang for the buck: a cost-effectiveness comparison between individual interviews and focus groups based on thematic saturation levels. Am J Eval. 2016;37:425–440.CrossRef
20.
Zurück zum Zitat Willis G. Cognitive Interviewing: A Tool for Improving Questionnaire Design. Thousand Oaks: Sage; 2005.CrossRef Willis G. Cognitive Interviewing: A Tool for Improving Questionnaire Design. Thousand Oaks: Sage; 2005.CrossRef
21.
Zurück zum Zitat Lincoln YS, Guba E. Naturalistic Inquiry. Beverly Hills, CA: Sage; 1985.CrossRef Lincoln YS, Guba E. Naturalistic Inquiry. Beverly Hills, CA: Sage; 1985.CrossRef
22.
Zurück zum Zitat Baker DW, Williams MV, Parker RM, et al. Development of a brief test to measure functional health literacy. Patient Educ Couns. 1999;38:33–42.CrossRefPubMed Baker DW, Williams MV, Parker RM, et al. Development of a brief test to measure functional health literacy. Patient Educ Couns. 1999;38:33–42.CrossRefPubMed
23.
Zurück zum Zitat Fagerlin A, Zikmund-Fisher BJ, Ubel PA, et al. Measuring numeracy without a math test: development of the/Numeracy Scale. Med Decis Mak. 2007;27:672–680.CrossRef Fagerlin A, Zikmund-Fisher BJ, Ubel PA, et al. Measuring numeracy without a math test: development of the/Numeracy Scale. Med Decis Mak. 2007;27:672–680.CrossRef
24.
Zurück zum Zitat Callahan CM, Unverzagt FW, Hui SL, et al. Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care. 2002;40:771–781.CrossRefPubMed Callahan CM, Unverzagt FW, Hui SL, et al. Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care. 2002;40:771–781.CrossRefPubMed
25.
Zurück zum Zitat Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1–24.CrossRef Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1–24.CrossRef
26.
Zurück zum Zitat Fernandez S, Chaplin W, Schoenthaler AM, et al. Revision and validation of the medication adherence self-efficacy scale (MASES) in hypertensive African Americans. J Behav Med. 2008;31:453–462.CrossRefPubMedPubMedCentral Fernandez S, Chaplin W, Schoenthaler AM, et al. Revision and validation of the medication adherence self-efficacy scale (MASES) in hypertensive African Americans. J Behav Med. 2008;31:453–462.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Walker DR, Juday TR, Manthena SR, et al. The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir. ClinicoEcon Outcomes Res. 2015;7:637–642.PubMedPubMedCentral Walker DR, Juday TR, Manthena SR, et al. The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir. ClinicoEcon Outcomes Res. 2015;7:637–642.PubMedPubMedCentral
28.
Zurück zum Zitat Petersen T, Townsend K, Gordon LA, et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int. 2016;10:310–319.CrossRefPubMed Petersen T, Townsend K, Gordon LA, et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int. 2016;10:310–319.CrossRefPubMed
29.
Zurück zum Zitat Cunningham EB, Amin J, Feld JJ, et al. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study. Int J Drug Policy. 2018;62:14–23.CrossRefPubMed Cunningham EB, Amin J, Feld JJ, et al. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study. Int J Drug Policy. 2018;62:14–23.CrossRefPubMed
31.
Zurück zum Zitat Phillips FH, Barnes D. Social support and adherence for military veterans with hepatitis C. Clin Spec. 2016;30:38–44.CrossRef Phillips FH, Barnes D. Social support and adherence for military veterans with hepatitis C. Clin Spec. 2016;30:38–44.CrossRef
32.
Zurück zum Zitat Zacks S, Beavers K, Theodore D, et al. Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol. 2006;40:220–224.CrossRefPubMed Zacks S, Beavers K, Theodore D, et al. Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol. 2006;40:220–224.CrossRefPubMed
33.
Zurück zum Zitat Zickmund S, Ho EY, Masuda M, et al. “They treated me like a leper”. Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18:835–844.CrossRefPubMedPubMedCentral Zickmund S, Ho EY, Masuda M, et al. “They treated me like a leper”. Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18:835–844.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. J Am Med Assoc. 1994;272:1749–1756.CrossRef Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. J Am Med Assoc. 1994;272:1749–1756.CrossRef
35.
Zurück zum Zitat Gellad WF, Thorpe CT, Steiner JF, et al. The myths of medication adherence. Pharmacoepidemiol Drug Saf. 2017;26:1437–1441.CrossRefPubMed Gellad WF, Thorpe CT, Steiner JF, et al. The myths of medication adherence. Pharmacoepidemiol Drug Saf. 2017;26:1437–1441.CrossRefPubMed
36.
Zurück zum Zitat Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005;41:88–96.CrossRefPubMed Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005;41:88–96.CrossRefPubMed
37.
Zurück zum Zitat Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis c virus infection: a systematic review. Ann Intern Med. 2017;166:637–648.CrossRefPubMedPubMedCentral Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis c virus infection: a systematic review. Ann Intern Med. 2017;166:637–648.CrossRefPubMedPubMedCentral
Metadaten
Titel
Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment
verfasst von
Corrine I. Voils
Heather A. King
Carolyn T. Thorpe
Dan V. Blalock
Ian M. Kronish
Bryce B. Reeve
Colleen Boatright
Ziad F. Gellad
Publikationsdatum
29.04.2019
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 10/2019
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05621-7

Weitere Artikel der Ausgabe 10/2019

Digestive Diseases and Sciences 10/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.